Although PI3Kδ does not function as a pivotal driver in PTEN-deficient tumors [11], inhibition of PI3Kβ in the tumor cells and PI3Kδ in the immune suppressive myeloid cells with AZD8186 provides a complementary approach to restoring antitumor immunity and enhancing effector T-cell function [31]. Here, PTEN is linked to neoplasm.